Outlook Therapeutics, Inc.

As of June 30, 2026, Outlook Therapeutics, Inc. carries a market capitalization of 256.51M, placing it among publicly traded companies globally. Its enterprise value stands at 262.80M, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.

Outlook Therapeutics, Inc.'s next confirmed earnings release is scheduled for December 18, 2026.

As of June 30, 2026, Outlook Therapeutics, Inc. has 187.10M shares outstanding.

These figures are as of June 30, 2026. The price-to-sales ratio is -111.96, and the price-to-book ratio stands at -28.20.

As of June 30, 2026, Outlook Therapeutics, Inc. maintains a current ratio of 0.81, meaning it holds 0.8x the short-term assets needed to cover near-term liabilities. The debt-to-equity ratio is -177.35, indicating conservative leverage, while an interest coverage ratio of -210.22 demonstrates limited ability to service its debt obligations.

These figures cover the twelve months ended June 30, 2026. Return on assets (ROA) is negative at -251.66, reflecting losses generated across the asset base. The company generates approximately -59,905.58 in revenue per employee across its workforce of 17.00, a quick read on workforce productivity versus industry peers. Inventory turnover of 0.24 indicates how many times Outlook Therapeutics, Inc. sells and replaces its inventory over a year, a key working capital efficiency ratio.

Over the twelve months ended June 30, 2026, Outlook Therapeutics, Inc. recorded an income tax benefit of -1.36M rather than an expense, typically from losses, carryforwards, or the release of a tax provision. The company reported a pretax loss of -54.86M and -53.50M in bottom-line net income, so the effective tax rate carries little signal until profitability returns.

These figures are as of the close on October 22, 2026.

Over the twelve months ended June 30, 2026, Outlook Therapeutics, Inc. generated -1.02M in revenue and converted that into -53.50M in net income, yielding earnings per share of -0.64. EBITDA reached -48.61M, while operating income came in at -48.70M.

As of June 30, 2026, Outlook Therapeutics, Inc. holds 9.84M in cash and equivalents against 16.13M in total debt, resulting in a net debt position of 6.11M. Total book value stands at -9.10M, with working capital of -4.82M providing operational flexibility.

Outlook Therapeutics, Inc. produced -49.15M in operating cash flow over the twelve months ended June 30, 2026.

Over the twelve months ended June 30, 2026, Outlook Therapeutics, Inc. posted a gross margin of 195.61, reflecting its pricing power and cost economics. The operating margin of 4,781.84 and net profit margin of 5,253.48 provide insight into operational efficiency.

These figures cover the twelve months ended June 30, 2026. Free cash flow yield is negative at -43.11: the business is consuming cash rather than generating it, so any dividend is not covered by free cash flow. Total shareholder yield is negative at -20.68, meaning Outlook Therapeutics, Inc. raised more capital through share issuance and new debt than it returned via dividends and buybacks.

Outlook Therapeutics, Inc.'s most recent stock split took place on March 14, 2024 with a 20:1 split ratio.

As of June 30, 2026, Outlook Therapeutics, Inc. has an Altman Z-Score of -37.44, below the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.